-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, researchers investigated the effectiveness of the BNT162b2 mRNA vaccine after mass vaccination in Israel.
Recently, researchers investigated the effectiveness of the BNT162b2 mRNA vaccine after mass vaccination in Israel.
Infections 14-20 days after the first vaccination, and at least 7 days after the second vaccination, the endpoint event data for the vaccinated vs.
unvaccinated population is as follows: SARS-COV-2 infection, 46% vs 92%; symptomatic Covid-19, 57% vs 94%; Covid-19 hospitalization, 74% vs 87%; severe Covid-19, 62% vs 92%.
14-20 days after the first vaccination, and at least 7 days after the second vaccination, the endpoint event data for the vaccinated vs.
unvaccinated population is as follows: SARS-COV-2 infection, 46% vs 92%; symptomatic Covid -19, 57% vs 94%; Covid-19 hospitalization, 74% vs 87%; severe Covid-19, 62% vs 92%.
Coronavirus disease
Recently, researchers investigated the effectiveness of the BNT162b2 mRNA vaccine after mass vaccination in Israel.
Infections 14-20 days after the first vaccination, and at least 7 days after the second vaccination, the endpoint event data for the vaccinated vs.
unvaccinated population is as follows: SARS-COV-2 infection, 46% vs 92%; symptomatic Covid-19, 57% vs 94%; Covid-19 hospitalization, 74% vs 87%; severe Covid-19, 62% vs 92%.
14-20 days after the first vaccination, and at least 7 days after the second vaccination, the endpoint event data for the vaccinated vs.
unvaccinated population is as follows: SARS-COV-2 infection, 46% vs 92%; symptomatic Covid -19, 57% vs 94%; Covid-19 hospitalization, 74% vs 87%; severe Covid-19, 62% vs 92%.
Coronavirus disease